MedVellum
MedVellum
Back to Library
Neurology
Geriatric Medicine
Primary Care

Parkinson's Disease

High EvidenceUpdated: 2025-12-22

On This Page

Red Flags

  • Early falls (consider atypical parkinsonism)
  • Early autonomic failure (MSA)
  • Poor levodopa response (atypical parkinsonism)
  • Rapid progression
  • Severe psychosis
  • Neuroleptic-induced parkinsonism
Overview

Parkinson's Disease

1. Topic Overview

Summary

Parkinson's disease (PD) is a progressive neurodegenerative disorder caused by loss of dopaminergic neurons in the substantia nigra pars compacta. It is characterised by the motor features of bradykinesia, rigidity, and rest tremor, along with numerous non-motor features including constipation, anosmia, sleep disturbance, and later cognitive impairment. Diagnosis is clinical. Treatment is primarily with levodopa (most effective) or dopamine agonists, with surgical options (DBS) for advanced disease. PD progresses over years, and management requires multidisciplinary support.

Key Facts

  • Definition: Neurodegenerative disorder due to dopaminergic neuron loss in substantia nigra
  • Prevalence: 1-2 per 1,000; increases with age (1% >60 years)
  • Diagnosis: Clinical — bradykinesia PLUS tremor or rigidity
  • Hallmark Pathology: Lewy bodies (α-synuclein)
  • First-Line Treatment: Levodopa (with carbidopa/benserazide)
  • Specialist Input: All patients should be referred to a specialist

Clinical Pearls

"Bradykinesia is Essential": You CANNOT diagnose Parkinson's disease without bradykinesia. It must be present along with at least one of: rest tremor or rigidity.

Asymmetry is Typical: PD classically starts unilaterally. Symmetric onset or early bilateral disease should raise suspicion of atypical parkinsonism.

Non-Motor Features Precede Motor: Anosmia, constipation, REM sleep behaviour disorder (RBD), and depression often precede motor symptoms by years — the "prodromal phase."

Why This Matters Clinically

PD is the second most common neurodegenerative disorder after Alzheimer's. Early recognition allows appropriate treatment initiation, improving quality of life. Differentiating PD from atypical parkinsonian syndromes and drug-induced parkinsonism is essential.


2. Epidemiology

Incidence & Prevalence

  • Prevalence: 1-2 per 1,000 population; ~1% of those >60 years
  • Incidence: 10-20 per 100,000 per year
  • Trend: Increasing due to ageing population
  • Global Impact: ~6 million people affected worldwide

Demographics

FactorDetails
AgeMean onset 60-65 years; 5-10% young-onset (<50)
SexMale:Female 1.5:1
EthnicityHigher in Caucasian/European
Trend"Parkinson's Pandemic" — fastest-growing neurological disorder

Risk Factors

Risk FactorAssociation
AgeStrongest risk factor
Male sex1.5x increased risk
GeneticsLRRK2, GBA, SNCA, PARK2 (especially young-onset)
Pesticide exposureParaquat, rotenone
Head injuryAssociated in some studies
Coffee/SmokingProtective (epidemiological association)

3. Pathophysiology

Mechanism

Step 1: Dopaminergic Neuron Loss

  • Progressive degeneration of dopaminergic neurons in substantia nigra pars compacta
  • By symptom onset, ~60-70% of neurons already lost

Step 2: Striatal Dopamine Deficit

  • Reduced dopamine in striatum (putamen)
  • Imbalance in basal ganglia direct/indirect pathways
  • → Motor symptoms

Step 3: α-Synuclein Aggregation

  • Lewy bodies: Intracellular inclusions containing α-synuclein
  • Lewy neurites: Abnormal processes
  • Spread of pathology (Braak staging): Brainstem → midbrain → cortex

Step 4: Non-Motor Systems Affected

  • Olfactory (anosmia)
  • GI (constipation, via enteric nervous system)
  • REM sleep (RBD)
  • Autonomic (orthostatic hypotension, bladder)
  • Cognitive (dementia, later)

Braak Staging

StageLocationClinical Correlate
1-2Olfactory bulb, lower brainstemAnosmia, constipation, RBD (prodromal)
3-4Substantia nigra, midbrainMotor symptoms
5-6NeocortexDementia

4. Clinical Presentation

Symptoms

Motor (Cardinal Features):

FeatureDescription
BradykinesiaSlowness of movement + decrement in amplitude with repetitive movements
Rest Tremor4-6 Hz, "pill-rolling"; present at rest, improves with action
RigidityLead-pipe rigidity; cogwheeling (tremor superimposed on rigidity)
Postural InstabilityLate feature; impaired postural reflexes

Non-Motor (Often Prodromal):

SystemSymptoms
AutonomicConstipation, urinary urgency, orthostatic hypotension, erectile dysfunction, hyperhidrosis
SleepREM sleep behaviour disorder (RBD), insomnia, daytime sleepiness
NeuropsychiatricDepression, anxiety, apathy, hallucinations, dementia
SensoryAnosmia (loss of smell), pain
OtherFatigue, seborrhoea, small handwriting (micrographia)

Signs

Red Flags (Suggest Atypical Parkinsonism)

[!CAUTION] Red Flags for Atypical Parkinsonism:

  • Early falls (within first year)
  • Poor or no response to levodopa
  • Symmetric onset
  • Early autonomic failure (MSA)
  • Early dementia (DLB)
  • Vertical gaze palsy (PSP)
  • Early bulbar dysfunction
  • Rapid progression
  • Pyramidal/cerebellar signs

Hypomimia ("masked facies")
Common presentation.
Reduced blink rate
Common presentation.
Stooped posture
Common presentation.
Shuffling gait, reduced arm swing
Common presentation.
Difficulty turning (en bloc turning)
Common presentation.
Festination (short, hurried steps)
Common presentation.
Micrographia (small handwriting)
Common presentation.
Hypophonia (soft voice)
Common presentation.
5. Clinical Examination

Structured Approach

Observation:

  • Facies (hypomimia)
  • Tremor at rest
  • Posture (flexed)
  • Gait (shuffling, reduced arm swing)

Assessment of Cardinal Features:

  • Bradykinesia: Finger tapping, hand movements, heel tapping (look for decrement)
  • Tremor: Rest tremor (distracted); pill-rolling
  • Rigidity: Assess tone (lead-pipe, cogwheeling)

Postural Stability:

  • Retropulsion test (pull test) — late feature

Special Tests

TestTechniqueSignificance
Finger tappingRepetitive thumb-index finger tappingBradykinesia: Decrement in amplitude/speed
Hand opening/closingRapid movementsSame decrement
Heel tappingFoot tapping on groundLower limb bradykinesia
Glabellar tap (Myerson sign)Repeated tapping on glabellaFailure to habituate (not specific)
Retropulsion testPull back on shouldersPostural instability (late)

6. Investigations

First-Line

Diagnosis is CLINICAL — based on history and examination.

TestPurpose
No routine bloods/imagingDiagnosis is clinical
MRI BrainExclude other causes (normal in PD; rule out vascular, NPH)

Specialist Investigations

TestWhenFindings
DaTSCAN (SPECT)Diagnostic uncertainty; differentiate PD from essential tremor/drug-inducedReduced dopamine transporter uptake (striatum)
MRI BrainRule out structural causes; atypical featuresNormal in PD; may show atrophy in atypical syndromes
Olfactory TestingSupportive (anosmia common in PD)Reduced smell in PD
Autonomic Function TestsIf autonomic features prominentAbnormal in MSA

Diagnostic Criteria (MDS Clinical Criteria)

Core Criteria:

  • Bradykinesia (ESSENTIAL) PLUS at least one of:
    • Rest tremor
    • Rigidity

Supportive Criteria:

  • Excellent response to dopaminergic therapy
  • Levodopa-induced dyskinesias
  • Rest tremor of a limb
  • Olfactory loss
  • Cardiac MIBG scintigraphy: Denervation

Exclusion Criteria:

  • Drug-induced parkinsonism
  • Atypical features (early falls, poor levodopa response, symmetric onset)

7. Management

Initial Treatment

AgentDose ExampleNotes
Levodopa + Dopa Decarboxylase InhibitorCo-careldopa 100/25mg TDS, titrateMost effective; first-line for most patients
Dopamine AgonistRopinirole 0.25mg TDS, titrate; Pramipexole; Rotigotine patchMay delay motor complications; more side effects
MAO-B InhibitorRasagiline 1mg OD; SelegilineMonotherapy for mild disease; adjunct

Advanced Therapies

Motor Fluctuations (Wearing Off):

  • More frequent levodopa dosing
  • Add COMT inhibitor (entacapone, opicapone)
  • Add MAO-B inhibitor (safinamide, rasagiline)
  • Add dopamine agonist

Dyskinesias:

  • Reduce individual levodopa doses
  • Amantadine (antidyskinetic)

Device-Aided Therapies:

  • Deep Brain Stimulation (DBS): STN or GPi; for motor fluctuations/dyskinesias
  • Levodopa-Carbidopa Intestinal Gel (LCIG): Continuous infusion via PEG-J
  • Apomorphine: SC infusion or rescue pen

Non-Motor Management

SymptomTreatment
DepressionSSRI, SNRI (avoid TCAs long-term)
PsychosisReduce dopaminergics; clozapine (first-line), quetiapine
DementiaRivastigmine (acetylcholinesterase inhibitor)
ConstipationMacrogol; fibre; hydration
Orthostatic HypotensionMidodrine; fludrocortisone
Insomnia / RBDClonazepam; melatonin

8. Complications

Disease-Related

ComplicationNotes
Motor fluctuationsWearing off, on-off phenomenon
DyskinesiasPeak-dose involuntary movements
FallsDue to postural instability
Dementia40-80% eventually develop
PsychosisHallucinations, delusions
Aspiration pneumoniaSwallowing dysfunction
DepressionCommon; undertreated

Treatment-Related

DrugSide Effects
LevodopaNausea (initially), dyskinesias, motor fluctuations
Dopamine agonistsImpulse control disorders (gambling, hypersexuality), daytime somnolence, hallucinations
MAO-B inhibitorsInsomnia, nausea
AmantadineLivedo reticularis, ankle oedema, hallucinations
DBSSurgical risks; speech/balance problems

9. Prognosis & Outcomes

Natural History

PD is progressive but variable. Most patients have good quality of life for many years with treatment. Motor complications (fluctuations, dyskinesias) typically develop after 5-10 years of levodopa therapy. Dementia and falls become prominent in advanced disease.

Outcomes

VariableOutcome
Life expectancyReduced by ~2-5 years compared to general population
Dementia40-80% eventually develop
Motor fluctuations50% by 5 years on levodopa
Dyskinesias30-50% by 5 years on levodopa

Prognostic Factors

Better Prognosis:

  • Tremor-dominant subtype
  • Younger onset
  • No cognitive impairment
  • Good levodopa response

Poorer Prognosis:

  • PIGD (postural instability gait difficulty) subtype
  • Older onset
  • Early cognitive impairment
  • Rapid motor progression

10. Evidence & Guidelines

Key Guidelines

  1. NICE NG71: Parkinson's Disease in Adults (2017) — Diagnosis, referral, pharmacological and non-pharmacological management.

  2. Movement Disorder Society Clinical Diagnostic Criteria (2015) — Gold standard diagnostic criteria.

Landmark Trials

PD MED (2014) — Initial PD treatment

  • RCT comparing levodopa vs levodopa-sparing strategies
  • Key finding: Levodopa provides best early motor control; no long-term disadvantage
  • Clinical Impact: Levodopa accepted as first-line for most patients

EARLYSTIM (2013) — Early DBS

  • RCT comparing DBS + medical therapy vs medical therapy alone
  • Key finding: DBS improves QoL in patients with early motor complications
  • Clinical Impact: Supports earlier DBS referral

Evidence Strength

InterventionLevelKey Evidence
Levodopa1aPD MED, meta-analyses
Dopamine agonists1aRCTs
MAO-B inhibitors1aRCTs
DBS1bEARLYSTIM, RCTs
Rivastigmine (dementia)1bEXPRESS trial

11. Patient/Layperson Explanation

What is Parkinson's Disease?

Parkinson's disease is a condition where certain nerve cells in your brain that produce a chemical called dopamine gradually stop working. Dopamine helps control movement, which is why Parkinson's causes stiffness, slowness, and tremor. It can also affect other things like sleep, mood, and bowel function.

Why does it matter?

Parkinson's is a progressive condition, meaning it gradually gets worse over time. However, with the right treatment and support, most people live well for many years. Medications can significantly improve symptoms.

What are the symptoms?

Main movement symptoms:

  • Tremor (shaking) — usually at rest
  • Slowness of movement
  • Stiffness
  • Balance problems (later on)

Other symptoms:

  • Loss of smell
  • Constipation
  • Sleep problems
  • Low mood or anxiety
  • Memory and thinking changes (later)

How is it treated?

  1. Medications: The main treatments replace or mimic dopamine:

    • Levodopa (most effective; usually becomes necessary)
    • Dopamine agonists
    • Other tablets to smooth out responses
  2. Therapies: Physiotherapy, speech therapy, occupational therapy

  3. Surgery (advanced cases): Deep brain stimulation (DBS) can help control symptoms when medications aren't working well enough

What to expect

  • Parkinson's progresses slowly — most people have many good years
  • Medications work well at first; can be adjusted over time
  • Regular follow-up with your specialist is important
  • Multidisciplinary team support (physio, OT, SALT, nurses) helps maintain function

When to seek help

Contact your team or GP if:

  • Symptoms are getting significantly worse
  • You're having problems with medication timing
  • You experience hallucinations or confusion
  • Falls are increasing
  • Mood is low and affecting daily life

12. References

Primary Guidelines

  1. National Institute for Health and Care Excellence. Parkinson's disease in adults (NG71). 2017. nice.org.uk/guidance/ng71

Key Studies

  1. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601. PMID: 26474316

  2. PD MED Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196-1205. PMID: 24928805

  3. Schuepbach WMM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications (EARLYSTIM). N Engl J Med. 2013;368(7):610-622. PMID: 23406026

Further Resources

  • Parkinson's UK: parkinsons.org.uk
  • European Parkinson's Disease Association: epda.eu.com


Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate guidelines and specialists for patient care.

Last updated: 2025-12-22

At a Glance

EvidenceHigh
Last Updated2025-12-22

Red Flags

  • Early falls (consider atypical parkinsonism)
  • Early autonomic failure (MSA)
  • Poor levodopa response (atypical parkinsonism)
  • Rapid progression
  • Severe psychosis
  • Neuroleptic-induced parkinsonism

Clinical Pearls

  • **"Bradykinesia is Essential"**: You CANNOT diagnose Parkinson's disease without bradykinesia. It must be present along with at least one of: rest tremor or rigidity.
  • **Asymmetry is Typical**: PD classically starts unilaterally. Symmetric onset or early bilateral disease should raise suspicion of atypical parkinsonism.
  • **Non-Motor Features Precede Motor**: Anosmia, constipation, REM sleep behaviour disorder (RBD), and depression often precede motor symptoms by years — the "prodromal phase."
  • **Red Flags for Atypical Parkinsonism:**
  • - Early falls (within first year)

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines